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The serpin SPI-3 and the hemagglutinin (HA) encoded by cowpox virus (CPV) block cell–cell fusion, and colocalize at the cell surface.
wtCPV does not fuse cells, but inactivation of either gene leads to fusion. SPI-3 mAb added to wtCPV-infected cells caused fusion, confirming
that SPI-3 protein at the cell surface prevents fusion. The SPI-3 mAb epitope mapped to an 85-amino acid region at the C-terminus. Removal of
either 44 residues from the SPI-3 C-terminus or 48 residues following the N-terminal signal sequence resulted in fusion. Interaction between SPI-3
and HA proteins in infected cells was shown by coimmunoprecipitation. SPI-3/HAwas not associated with the A27L ‘‘fusion’’ protein. SPI-3 and
HAwere able to associate in uninfected cells in the absence of other viral proteins. The HA-binding domain in SPI-3 resided in the C-terminal 229
residues, and did not include helix D, which mediates cofactor interaction in many other serpins.
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Poxviruses have large, complex virions, linear dsDNA
genomes, and replicate within the cytoplasm (Moss, 2001).
Many aspects of the poxvirus lifecycle have been extensively
characterized, including early, intermediate and late transcrip-
tion, and the assembly of virions (Smith et al., 2002). The
most numerous virions produced are intracellular mature virus
(IMV), an enveloped form that is fully infectious but not
thought to be important in the spread of infection during a
natural infection. Extracellular enveloped virus (EEV) con-
tains an additional membrane relative to IMV, and is needed
for efficient dissemination within the host (Payne, 1980),
despite making up only a small proportion of total infectious
virus. The mechanisms by which EEV and IMV enter cells are
not completely understood, and remain active areas of
investigation.
One of the components of the EEV envelope is the SPI-3
protein. Immunogold EM revealed that SPI-3 was present in0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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three functional serine proteinase inhibitors (serpins) encoded
by orthopoxviruses. The other two orthopoxvirus serpins are
SPI-2, also known as crmA (cytokine response modifier A),
and SPI-1. SPI-2/crmA is a cross-class proteinase inhibitor
with both anti-inflammatory and antiapoptosis activity (Turner
et al., 1999). SPI-1 is involved in conferring full host-range on
wild-type (wt) rabbitpox virus, and in vitro is thought to be
active against cathepsin G (Moon et al., 1999). SPI-3 is
required to inhibit cell–cell fusion following infection with
orthopoxviruses (Law and Smith, 1992; Turner and Moyer,
1992; Zhou et al., 1992), and purified SPI-3 protein inhibits
plasmin, urokinase, and tissue-type plasminogen activator in
vitro (Turner et al., 2000). For SPI-3, the P1 residue at the
center of the reactive center loop (RCL) is arginine, which is
consistent with inhibition of proteinases that cleave after basic
residues. However, mutations in the RCL of SPI-3 that
destroyed proteinase inhibition did not affect control of cell–
cell fusion (Turner and Moyer, 1995), indicating that the SPI-3
protein is bifunctional.
The orthopoxvirus hemagglutinin (HA) is required in
addition to SPI-3 to prevent cell–cell fusion (Ichihashi and
Dales, 1971), and like SPI-3 is also a component of EEV
(Payne, 1979). Immunofluorescence studies showed that HA06) 88 – 99
www.e
Fig. 1. Adding SPI-3 monoclonal antibody during infection with wild-type
CPV induces fusion. CV-1 cells were infected with wtCPVat a multiplicity of 5
in the absence (A) or presence (B) of SPI-3 monoclonal antibody at 10 Ag/ml,
and photographed at 3 days p.i.
P.C. Turner, R.W. Moyer / Virology 347 (2006) 88–99 89and SPI-3 were colocalized at the surface of infected cells
(Brum et al., 2003). Although SPI-3 is membrane-associated,
the protein does not contain any predicted transmembrane
domain. HA and SPI-3 are components of EEV, but neither
protein is required for virion morphogenesis or for EEV
infectivity. Despite the conservation of SPI-3 in orthopox-
viruses, animal experiments have not shown any pronounced
attenuation of CPV or vaccinia virus (VV) mutants lacking
SPI-3 (Law and Smith, 1992; Thompson et al., 1993). In
contrast, deletion of HA does attenuate vaccina WR (Flexner et
al., 1987; Lee et al., 1992; Shida et al., 1988).
The biological significance of cell–cell fusion following
poxvirus infection is unclear. Presumably, fusion between
infected cells reflects the entry of poxvirus virions into cells
by a process involving fusion between the envelope of IMVand
the cell membrane. Currently, EEV is thought to dissociate at the
cell surface by a non-fusogenic process to release IMV (G.L.
Smith, personal communication). IMV then enters the cell by
direct fusion at neutral pH (Carter et al., 2005; Doms et al., 1990;
Janeczko et al., 1987). IMVadded to cells in large quantities and
then treated briefly at acid pH can induce cell–cell fusion known
as ‘‘fusion from without’’ (Gong et al., 1990). Antibody mAbC3
against the A27L protein, a component of IMV, neutralizes IMV
(Rodriguez et al., 1985) and blocks cell–cell fusion (Rodriguez
et al., 1987), and based on this finding A27L has been referred to
as the 14 kDa fusion protein. mAbC3 blocked fusion of labeled
IMV with cells in an assay involving dilution of the fluorescent
probe R18 (Doms et al., 1990). However, a VV recombinant
with an IPTG-inducible A27L gene was able to form fully
infectious IMV in the absence of IPTG (Rodriguez and Smith,
1990), suggesting that entry of IMV does not require A27L.
More recent data using vYFP-A4/DA27 with a complete
deletion of A27 (Ward, 2005) showed that IMV lacking A27
added directly to cells was still able to mediate fusion from
without (Senkevich and Moss, 2005), demonstrating that A27 is
not required for cell–cell fusion. The A28 protein, a component
of the IMV membrane (Senkevich et al., 2004a), is absolutely
required for virus entry (Senkevich et al., 2004b). Interestingly,
A28 is needed both for fusion from without (by added virions)
and for fusion from within (by virions produced from infected
cells) (Senkevich et al., 2004b), which strongly suggests that
fusion and virus entry are closely related processes. A second
protein, H2, has almost identical properties to A28, and forms a
complex with A28 that may mediate virus fusion with cells
(Senkevich and Moss, 2005).
HA and SPI-3 are both glycoproteins. The SPI-3 protein of
cowpox virus (CPV) has four N-linked glycosylation sites that
are all utilized, but glycosylation is not required for the
inhibition of fusion by SPI-3, or for localization of SPI-3 to the
cell membrane (Brum et al., 2003). Retention of SPI-3 at the
cell surface was, however, abrogated by inactivation of HA
(Brum et al., 2003), implying that there may be an interaction
between the two proteins. We show here that SPI-3 is retained
at the cell surface by binding to HA, and that the interaction
between HA and SPI-3 does not depend on any other viral
proteins. SPI-3 mutants that are inactive as proteinase
inhibitors are still able to associate with HA, consistent withearlier data that such mutants are still capable of fusion
inhibition (Turner and Moyer, 1995).
Results
SPI-3 monoclonal antibody induces fusion in cells infected
with wild-type cowpox virus
In view of reports that the addition of an anti-HA
monoclonal antibody was able to cause fusion during infection
with wild-type (wt) VV strain IHD-J (Seki et al., 1990), we
tested the SPI-3 monoclonal antibody 4A11-4A3 generated
against purified SPI-3 protein (Brum et al., 2003) for its ability
to induce cell–cell fusion in wtCPV infection. SPI-3 mAb at 10
Ag/ml had no effect on a confluent monolayer of uninfected
CV-1 cells over a period of 3 days (data not shown). CV-1 cells
infected with wtCPV gave a cytopathic effect with individual
cell rounding, but no evidence of fusion between infected cells
(Fig. 1A). The presence of SPI-3 mAb at 10 Ag/ml throughout
infection with wtCPV resulted in extensive cell–cell fusion
(Fig. 1B) resembling that seen on infection with a CPV or VV
mutant deleted for SPI-3 (Law and Smith, 1992; Turner and
Moyer, 1992; Zhou et al., 1992). With reduced input of wtCPV
such that individual plaques were visible, addition of SPI-3
mAb resulted in syncytial plaques (data not shown). Clearly,
the epitope for the SPI-3 mAb is accessible on the surface of
wtCPV-infected cells, and binding of SPI-3 mAb interferes
with the inhibition of fusion mediated by SPI-3.
Mapping of the epitope for the SPI-3 mAb
Nested deletions of SPI-3 were used to localize the epitope for
the SPI-3 mAb in order to gain possible insights into the
mechanism of fusion inhibition by SPI-3. The deletion mutants
(Table 1) were constructed using a PCR-based strategy, and
sequenced to confirm that no errors had been introduced. Each
deletion mutant was successfully expressed in vitro using a
coupled transcription/translation system, and the radiolabeled
products tested for the ability to be immunoprecipitated by the
SPI-3 mAb. Of the C-terminal deletion mutants C2 through C6,
the smallest deletion C2 which lacked only 44 amino acids was
not immunoprecipitated, and C3 through C6 which contained
longer deletionswere likewise not immunoprecipitated (Fig. 2A).
Table 1
SPI-3 deletions
Construct Residues present
wt SPI-3 1–373
SPI-3 C2 1–329
SPI-3 C3 1–286
SPI-3 C4 1–223
SPI-3 C5 1–159
SPI-3 C6 1–87
SPI-3 7N 71–373
SPI-3 SS-7N 1–22; 71–373
SPI-3 SS-8N 1–22; 145–373
SPI-3 9N 223–373
SPI-3 SS-9N 1–22; 223–373
SPI-3 10N 289–373
SPI-3 SS-10N 1–22; 289–373
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residues remaining), 9N (151 residues), and 10N (85 residues)
diagrammed in Fig. 2A were all recognized by the mAb,
enabling us to localize the epitope to within a C-terminal 85-
amino acid region from residues 289 to 373 (Fig. 2B) which
includes the RCL. Cleavage of radiolabeled SPI-3 with
urokinase, presumably at the P1–P1V bond in the RCL, resulted
in a fragment of approximately 39 kDa which was alsoFig. 2. Mapping of the epitope for SPI-3 mAb. (A) Recognition of SPI-3 C-terminal
plus indicates ability of radiolabeled protein to be immunoprecipitated by the SPI-3 m
wild-type (wt) SPI-3 protein are indicated. (B) The sequences of SPI-3 mutants near
the region at the C-terminus of wt SPI-3, with the locations of the P14 (Thr) and P1 (
10N is shown, which contains the SPI-3 epitope. The black line indicates the region o
3 RCL substitution mutants P1/P1V, P5/P5V, and P17/P10 are shown, with altered res
expasy.org using the crmA crystal structure (Renatus et al., 2000; Simonovic et al.
reactive center loop (RCL, bracketed) at the ‘‘top’’ of the molecule is indicated. The p
SPI-3 epitope is shown in black, with the remainder of the protein in grey. The black
s5A of beta-sheet A, and a loop at the bottom of the molecule.immunoprecipitated by SPI-3 mAb. To investigate the possi-
bility that a complex of urokinase and both large and small SPI-
3 fragments was being immunoprecipitated by recognition of
the smaller SPI-3 fragment, we cleaved unlabeled His-SPI-3
protein with urokinase, and immunoblotted with SPI-3 mAb.
Only the larger cleavage fragment was detected by immuno-
blotting, indicating that the epitope lies within this fragment.
The epitope is likely located within the 52-amino acid region of
overlap between 10N and cleaved SPI-3 indicated by the thick
black line in Fig. 2B. The location of this portion of SPI-3
within the predicted structure is indicated in black in Fig. 2C,
and spans part of the RCL at the top of the SPI-3 model, one of
the strands in h-sheet A, and a loop at the bottom. In addition,
the SPI-3 substitution mutants which alter positions P1/P1V, P5
through P5V, and P17 through P10 (Fig. 2B) were all recognized
by SPI-3 mAb, suggesting that the epitope lies to the N-terminal
side of P17, although a contribution to the epitope from the P9–
P6 residues located in between the P17/P10 and P5/P5V
mutations cannot be ruled out.
The effects of mutations in SPI-3 and HA on fusion inhibition
Although binding of SPI-3 mAb to SPI-3 protein located on
the surface of infected cells prevents fusion inhibition, thedeletions C2–C6 and N-terminal deletions 7N, 9N, and 10N by SPI-3 mAb. A
Ab. The locations of the signal sequence (SS) and reactive center loop (RCL) in
the C-terminus, which are all recognized by the SPI-3 mAb. The top line shows
Arg) residues marked by arrows. The 85-amino acid sequence of SPI-3 deletion
f overlap between 10N and urokinase-cleaved SPI-3. The sequences of the SPI-
idues underlined. (C) Model of SPI-3 structure created with SWISS-MODEL at
, 2000) and other serpins as templates. The P1 Arg residue located within the
osition of the 52-amino acid region underlined in panel B that encompasses the
portion includes part of the reactive center loop at the top of the molecule, strand
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3 is important for this activity. The P1/P1V, P5/P5V, and P17/
P10 substitution mutations in the RCL prevented proteinase
inhibition (Turner et al., 2000), but had no effect on fusion
inhibition (Turner and Moyer, 1995), suggesting that proteinase
inhibition and control of fusion were independent processes.
The C-terminal SPI-3 deletion mutants C2 through C6 were
tested for fusion inhibition by a transient transfection assay
(Turner and Moyer, 1995). Briefly, CV-1 cells were infected
with a vTF7-3 (VV-T7 RNA Pol) derivative lacking the SPI-3
gene, and transfected with pTM1 derivatives carrying either a
wtSPI-3 control gene or one of the deleted forms of the SPI-3
gene. Transfection with the empty vector pTM1 had no effect
on the fusion caused by vTF7-3DSPI-3 (Fig. 3B). However,
expression of functional wild-type SPI-3 protein from the T7
promoter suppresses the cell fusion that otherwise results from
infection with vTF7-3DSPI-3 (Fig. 3C). Removal of the 44 C-
terminal amino acids in the SPI-3 C2 deletion destroyed the
ability of SPI-3 to inhibit fusion (Fig. 3D). Deletions C3Fig. 3. The activity of N- and C-terminal SPI-3 deletion mutants in fusion inhibition.
and transfected with: (B) pTM1 vector DNA; (C) pTM1-SPI-3; (D) pTM1-SPI-3 C
results of the fusion inhibition assays for SPI-3 deletions.through C6 extending further toward the N-terminus were also
inactive (summarized in Fig. 3G). For mutants C2 through C6,
the lack of binding to SPI-3 mAb paralleled the inability to
inhibit fusion. We were unable to confirm expression of C2
through C6 by immunoblotting with SPI-3 mAb since the
antibody does not recognize these deleted proteins, but we did
show subsequently that FLAG-tagged versions of C2 and C4
were detectable with FLAG mAb in transfected cells by
immunofluorescence (Fig. 10) and by immunoprecipitation
(data not shown). The N-terminal deletions 7N (Fig. 3E), 9N,
and 10N (data not shown) had no activity in fusion inhibition,
as expected since removal of the signal sequence alone
(residues 1–15) was sufficient to prevent the inhibition of
fusion (Brum et al., 2003). The signal sequence was added to
the smallest deletion 7N to create SPI-3 SS-7N, which would
be expected to transit through the endoplasmic reticulum and
Golgi. The results indicated that deletion of wtSPI-3 residues
23–70 in SPI-3 SS-7N also prevented fusion inhibition (Fig.
3F). SPI-3 SS-8N, SPI-3 SS-9N, and SPI-3 SS-10N with the(A) CV-1 cells infected with vTF7-3. (B–F) Cells infected with vTF7-3D SPI-3
2; (E) pTM1-SPI-3 7N; (F) pTM1-SPI-3 SS-7N. (G) Cartoon summarizing the
Fig. 5. Coimmunoprecipitation of SPI-3 and HA. CV-1 cells were infected with
wtCPV (indicated by ‘‘wt’’ above lanes 1 and 3) or with CPV D SPI-3 (‘‘D’’,
lanes 2 and 4), labeled with 35S-Met TranSlabel from 3 h to 7 h p.i., and
cytoplasmic extracts immunoprecipitated with SPI-3 mAb 4A11-4A3 (lanes 1
and 2) or with polyclonal HA antibody (lanes 3 and 4). The products were
subjected to electrophoresis on a 10% acrylamide gel followed by autoradi-
ography. The bracket indicates SPI-3, and the arrow HA.
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deletions were similarly inactive in fusion inhibition (Fig. 3G).
SPI-3 SS-7N and SS-8N were readily detected in transfected
BSR-T7 cells by immunofluorescence (Fig. 10); however, SS-
9N (Fig. 10) and SS-10N (data not shown) were not, indicating
that the SS-9N and SS-10N deletions had perturbed protein
stability. The fact that virtually any deletion of SPI-3 destroys
the ability to inhibit fusion suggests that the overall serpin
structure is an important component of fusion inhibition.
The HA protein was not subjected to a detailed mutational
analysis; however, the effect of removal of the HA transmem-
brane domain (TM; residues 262–284) was assessed. CV-1
cells infected with CPV HA were transfected with pSC65
derivatives carrying wtHA (297 amino acids) or HA()TM
deleted for residues 262–297 (Fig. 4A). In this instance, the
HA gene in pSC65 is under the control of a synthetic early/late
poxvirus promoter (Chakrabarti et al., 1997). Compared to the
fusion observed with CPV HA, expression of wt HA from the
plasmid completely prevented fusion (Figs. 4B and C), but
HA()TM lacking the region at the C-terminus including the
TM domain had no activity (Fig. 4D). Expression of wtHA and
HA()TM from the transfected cells was confirmed by
immunoblotting cell extracts with HA mAb. In addition, wtHA
was absent from the medium, but HA()TM was present in
significant quantities in the medium, consistent with secretion
(data not shown). Anchoring of HA at the cell membrane is
presumably required for HA to inhibit fusion.
Coimmunoprecipitation of SPI-3 and HA
Our previous observation that retention of SPI-3 at the cell
surface is dependent on the presence of HA (Brum et al., 2003)
implies that SPI-3 may interact directly with HA, or that SPI-3
and HA are both members of the same multiprotein complex. In
order to investigate association of SPI-3 with HA and with other
viral proteins, cells were infected with wtCPV or CPVDSPI-3,
and radiolabeled. The protocol used results in strong labeling of
viral proteins, but little labeling of cellular proteins whoseFig. 4. Removal of the transmembrane domain from HA prevents control of fusion.
wild-type HA, and removal of the C-terminal region spanning the TM domain in
transfected (B) or transfected with pSC65-HA (C) or pSC65-HA()TM (D), and pexpression is rapidly inhibited following infection. Wt CPV
extracts immunoprecipitated with SPI-3 mAb gave an intense
diffuse band at approximately 55 kDa, corresponding to the
expected size for glycosylated SPI-3 protein (Fig. 5, lane 1). In
addition, there was a band at approximately 85 kDa (Fig. 5, lane
1) that was a potential interacting protein. Both the 55 kDa and
85 kDa bands were absent in immunoprecipitation of a control
extract from infection with CPVDSPI-3 (Fig. 5, lane 2). The
apparent mobility of 85 kDa was the same as the reported size of
one of the two observed forms of vaccinia virus HA (Brown et
al., 1991), and was consistent with the interacting protein being
CPV HA. We obtained both polyclonal serum and mAb against
VVHA to test this hypothesis. Immunoprecipitation of a wtCPV
extract with a polyclonal HA antibody resulted in the same
protein profile (Fig. 5, lane 3) as seen with SPI-3 mAb (Fig. 5,(A) Location of the signal sequence (SS) and transmembrane domain (TM) in
HA()TM. (B, C, D) CV-1 cells were infected with CPV HA and mock-
hotographed at 24 h p.i.
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recovered. The anti-HA antiserum precipitated only the 85 kDa
protein from a CPVDSPI-3 extract (Fig. 5, lane 4), confirming
that the 55 kDa band was SPI-3. Control immunoprecipitation
with HA antiserum of extracts from cells infected with CPV
HA resulted in no detectable protein at 85 kDa (data not
shown), consistent with the protein of this mobility being HA.
Immunoprecipitation of wtCPV extracts with the mAb 1H831
against HA instead of the HA polyclonal Ab also gave
coimmunoprecipitation of SPI-3 (data not shown).
The effect of the SPI-3 RCLmutations on the association with
HA was evaluated by coimmunoprecipitation experiments.
Since recombinant CPV bearing the SPI-3 RCL mutations were
not available, a transfection strategy was employed. A double
mutant CPV HA SPI-3::gfp was constructed by recombination
between CPV HA and a plasmid containing SPI-3 with gfp
inserted in place of the central portion of the SPI-3 gene. pSC65
derivatives carrying HA and either wt SPI-3, SPI-3 P17/P10 or
SPI-3 P1/P1Vwere transfected into cells infected with CPV HA
SPI-3::gfp. The infected and transfected cells were labeled with
35S-Met (TranSlabel), and extracts immunoprecipitated with
either SPI-3 mAb or HA mAb. HA protein expressed alone was
not immunoprecipitated by SPI-3 mAb, but was precipitated
with SPI-3 whenHA and SPI-3 were coexpressed (Fig. 6, lanes 2
and 4). HA was not strongly labeled in these experiments and
migrated as a diffuse band above the position of SPI-3. The
reciprocal experiment indicated that the HA mAb did not
immunoprecipitate SPI-3 (lane 11) unless HAwas coexpressed
(lane 12). HA and SPI-3 P17/P10 were coimmunoprecipitated
both by SPI-3 mAb (lane 6) and byHAmAb (lane 14). Similarly,
the SPI-3 P1/P1Vmutant protein interacted with wt HA as judged
by coimmunoprecipitation with SPI-3 mAb (lane 8) and with
HA mAb (lane 16). Comparable results were obtained with the
SPI-3 P5/P5V mutation. The association between SPI-3 and HA
thus did not depend on SPI-3 functioning as a proteinase
inhibitor. This result is consistent with previous observationsFig. 6. SPI-3 RCL mutations do not prevent interaction with HA. CV-1 cells were in
pSC65-HA and either pSC65-SPI-3, pSC65-SPI-3 P17/P10, or pSC65-SPI-3 P
Radiolabeled extracts were immunoprecipitated with SPI-3 mAb (lanes 1–8) or with
by the arrow, as in Fig. 5.that mutations in the SPI-3 RCL did not affect fusion inhibition
(Turner and Moyer, 1995).
SPI-3 and HA are not associated with A27L
We looked for an interaction of SPI-3/HA with the A27L
product, the 14K ‘‘fusion protein’’, using mAbC3 (Rodriguez et
al., 1985). This mAb against the A27 protein is able to block
fusion induced by infection with VV WR mutant 87-4
(Rodriguez et al., 1987), by low pH treatment of infected cells
(fusion from within) (Gong et al., 1990; Rodriguez et al., 1985),
and by infection with VVDSPI-3 (Turner and Moyer, 1992),
suggesting that the A27L protein is required for cell–cell fusion.
Radiolabeled extracts of cells infected with wtCPV were
immunoprecipitated with mAbC3, revealing a band at approx-
imately 15 kDa marked by the asterisk that was the A27L
product, but there was no coimmunoprecipitation of HA or SPI-
3 (Fig. 7, lane 2). Immunoprecipitation of the same wtCPV
extract with SPI-3 mAb gave detectable SPI-3 and HA (Fig. 7,
lane 4, arrows); however, there was no indication that the A27L
protein was coimmunoprecipitated. Neither HA nor SPI-3 was
immunoprecipitated from an extract of CPVDSPI-3-infected
cells (Fig. 7, lane 5). The SPI-3 mAb did bring down small
amounts of proteins at about 200 kDa and 38 kDa (Fig. 7, lane 4),
but these proteins were also visible in wtCPV extracts which
were incubated with protein A-Sepharose in the absence of
antibody (Fig. 7, lane 7), indicating that they were not associated
with the SPI-3/HA complex. To date, we have not detected any
virus proteins other than HA that interact with SPI-3.
SPI-3 localizes to the surface of BSR-T7 cells expressing HA in
the absence of other virus proteins
In order to assess interaction between SPI-3 and HA in the
absence of other virus proteins, we made use of BSR-T7 cells
that express the T7 RNA polymerase constitutively (Buchholz etfected with CPV HA SPI-3::gfp and transfected with pairwise combinations of
1/P1V, together with single plasmid controls, as indicated above the lanes.
HA mAb (lanes 9–16). The position of SPI-3 is marked by the bracket and HA
Fig. 8. Surface localization of SPI-3 in transfected BSR-T7 cells in the presence of
HA. BSR-T7 cells were transfected with pTM1-SPI-3 (A, C) or with pTM1-SPI-3
and pTM1-HA (B,D). Cells were either washedwith PBS (A,B) or permeabilized
withmethanol (C, D) before addition of SPI-3mAb. Following PFA fixation, goat
anti-mouse FITC secondary antibody was added to visualize SPI-3.
Fig. 7. Immunoprecipitation from wtCPV-infected cells does not reveal any
association between SPI-3/HA and A27L (the 14 K ‘‘fusion’’ protein). Extracts
were made from CV-1 cells that had been mock-infected (U, lanes 1, 3, 6) or
infected with wtCPV (wt, lanes 2, 4, 7) or CPVD SPI-3 (D, lane 5), and labeled
with 35S-Met from 3 h to 7 h p.i. Immunoprecipitation was done with mAbC3
against the A27L 14K protein (lanes 1, 2), with SPI-3 mAb (lanes 3, 4, 5) or
with no antibody (lanes 6, 7), and the products visualized by SDS-PAGE and
autoradiography. The asterisk indicates the position of the A27L protein in lane
2, and arrows mark SPI-3 and HA bands in lane 4.
Fig. 9. Purified SPI-3 protein binds to transfected cells expressing HA on the
surface. BSR-T7 cells were transfected with pTM1 (A) or pTM1-HA (B), and
after 18 h, purified SPI-3 protein was added at 20 Ag/ml. After incubation for
2 h, followed by three washes, bound SPI-3 protein was visualized by
immunofluorescence using SPI-3 mAb and goat anti-mouse FITC.
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plasmids containing SPI-3 and HA under the control of the T7
promoter, and the localization of SPI-3 was determined by
immunofluorescence. Live, untreated cells were reacted with
SPI-3 mAb to detect SPI-3 at the cell surface, or cells were
permeabilized with methanol to visualize internal SPI-3 protein.
In both cases, transfected BSR-T7 cells were fixed with
paraformaldehyde after reaction with the primary antibody, to
reduce the problem of paraformaldehyde fixation making the
cells permeable to primary antibody (M. Law, personal
communication). BSR-T7 cells transfected with pTM1-SPI-3
alone gave no detectable SPI-3 at the surface of unpermeabilized
cells (Fig. 8A), but intracellular SPI-3 was clearly detectable in
permeabilized cells (Fig. 8C). In contrast, cotransfection with
pTM1-SPI-3 and pTM1-HA gave strong SPI-3 expression at the
surface of unpermeabilized cells (Fig. 8B), as well as internally
(Fig. 8D). Retention of SPI-3 at the cell surface therefore did not
require any additional virus proteins besides HA, implying that
SPI-3 and HA interact directly. Although in BSR-T7 cells SPI-3
required HA to localize at the cell surface, HAwas present at the
surface both with and without coexpression of SPI-3 (data not
shown). These results parallel the situation in infected cells,
where SPI-3 fails to localize at the cell membrane in cells
infected with CPVHA, but HA is at the surface in cells infected
with wtCPVor with CPVDSPI-3 (Brum et al., 2003). Although
expression of the viral proteins SPI-3 and HA is sufficient for
surface localization, we cannot exclude the possibility that a
cellular protein is also involved.
Purified SPI-3 protein binds to the surface of transfected cells
expressing HA
We were unable to find any association between SPI-3 and
HA proteins following coexpression by coupled transcription/
translation in vitro, even in the presence of canine microsomal
membranes (data not shown). The interaction between the twoproteins may take place during their transit through the ER and
Golgi. We asked if cells bearing HA on their surface could
specifically bind exogenously added SPI-3 protein. HA localizes
to the cell surface normally in the absence of SPI-3 in either
infected cells (Brum et al., 2003) or in transfected cells (data not
shown). Purified SPI-3 protein expressed in the vaccinia/T7
system was tested for binding to BSR-T7 cells that were either
transfected with empty vector pTM1 or transfected with pTM1-
HA (Fig. 9). Surface-bound SPI-3 protein was visualized by
immunofluorescence with SPI-3 mAb using unpermeabilized
cells. The added SPI-3 protein carried a His tag at the N-
terminus, and lacked the signal sequence. SPI-3 protein added at
20 Ag/ml did not bind to BSR-T7 cells transfected with the
vector pTM1 alone (Fig. 9A), but did bind to BSR-T7 cells
expressing HA (Fig. 9B). SPI-3 can therefore associate with HA
post-translationally, and cotrafficking through the ER and Golgi
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purified SPI-3 protein lacked glycosylation since the signal
sequence had been removed, and N-linked glycosylation is
clearly not required for binding to HA in this instance. This result
is consistent with the phenotype of the virus recombinant CPV
SPI-3 N-glyc(), which was engineered to have all 4 N-linked
glycosylation sites in SPI-3 inactivated by site-directed muta-
genesis, but was still able to inhibit cell–cell fusion, and gave
normal cell surface localization of SPI-3 N-glyc() following
infection (Brum et al., 2003).
The effect of SPI-3 C- and N-terminal deletions on cell surface
localization with HA
SPI-3 deletion mutants extending from either the C-terminus
or the N-terminus following the signal sequence were bothFig. 10. Effect of SPI-3 deletions on localization in transfected BSR-T7 cells express
FLAG (A, D), pTM1-SPI-3-C2-FLAG (B, E), pTM1-SPI-3-C4-FLAG (C, F), pTM1
SPI-3 protein was detected with anti-FLAG mAb (A–F) or with SPI-3 mAb (G–L).
E, F, J, K, and L were permeabilized with methanol before addition of mAb. Fixatunable to prevent cell–cell fusion (Fig. 3). Was the loss of
activity caused by failure to associate with HA at the cell surface,
or by correct localization coupled with an intrinsic loss of fusion
inhibition? Detection of SPI-3 by immunofluorescence at the
surface of unpermeabilized HA-expressing cells provided a
convenient assay for interaction between various SPI-3 mutants
and HA. BSR-T7 cells were transfected with pTM1-HA and also
with plasmids carrying FLAG-tagged versions of SPI-3 dele-
tions C2 and C4. The addition of a C-terminal FLAG tag
(DYKDDDDK) was necessary for detection since the C2 and C4
deletions removed the SPI-3 epitope (Fig. 2A). A pTM1
derivative containing full length SPI-3 with the FLAG tag
appended at the C-terminus was included as a positive control.
SPI-3-FLAG was detectable with FLAG mAb at the surface of
unpermeabilized cells that had been transfected with plasmids
expressing SPI-3-FLAG and HA (Fig. 10A); however, SPI-3-ing HA. BSR-T7 cells were transfected with pTM1-HA and with pTM1-SPI-3-
-SPI-3 SS-7N (G, J), pTM1-SPI-3 SS-8N (H, K), or pTM1-SPI-3 SS-9N (I, L).
Cells in panels A, B, C, G, H, and I were unpermeabilized and cells in panels D,
ion and detection with goat anti-mouse FITC were as in Fig. 8.
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if HA was absent (data not shown). Therefore, addition of the
8 amino acid FLAG sequence to wt SPI-3 did not perturb SPI-3
localization, and did not affect fusion inhibition in the
transfection assay (data not shown). Coexpression of SPI-3-
C2-FLAG and HA did not result in localization of the FLAG
epitope at the cell surface (Fig. 10B), although SPI-3-C2-FLAG
was visible inside cells (Fig. 10E). Similarly, the more extensive
deletion SPI-3-C4-FLAG when expressed with HA was only
detectable in permeabilized cells (Figs. 10C, F). Radiolabeling
of transfected cells confirmed that SPI-3 C2-FLAG and SPI-3
C4-FLAG proteins were expressed and were of the appropriate
size (data not shown). Removal of the 44 amino acids from the
C-terminus of SPI-3 to create the C2 deletion presumably
disrupted the interaction between SPI-3 and HA that is required
for SPI-3 to be retained at the cell surface.
The N-terminal SPI-3 deletions SS-7N, SS-8N, SS-9N and
SS-10N were tested in a similar manner to determine if the
mutant SPI-3 protein was present on the surface of unpermea-
bilized BSR-T7 cells when HAwas coexpressed. Each of these
constructs contained the signal sequence at the N-terminus to
permit normal trafficking within the cell, and detection in IF
was by the SPI-3 mAb 4A11-4A3. SPI-3 SS-7N and SPI-3 SS-
8N were readily detectable in permeabilized cells when
expressed with HA (Figs. 10J, K). In contrast SPI-3 SS-9N
(Fig. 10L) and SPI-3 SS-10N (data not shown) were not visible
inside cells by IF, and could not be detected by immunoblotting
either in cell extracts or in concentrated supernatants from
transfected cells (data not shown). Therefore, no conclusions
could be drawn concerning the interaction of SPI-3 SS-9N and
SS-10N with HA. However, SPI-3 SS-7N and SPI-3 SS-8N
were also visible on unpermeabilized cells (Figs. 10G, H),
suggesting that these deleted forms of SPI-3 were still capable
of binding to HA on the surface. SPI-3 SS-8N was
coimmunoprecipitated with FLAG-tagged HA by FLAG
mAb following expression of the two proteins in CV-1 cells
infected with vTF7-3DSPI-3 (data not shown). The binding site
for HA presumably resides in the 229 amino acid residues
remaining in SPI-3 SS-8N. The SS-8N deletion removes from
SPI-3 helices A, B, C, D and E, two strands of h-sheet A, and
one strand of h-sheet B, indicating that the interaction between
SPI-3 and HA does not require any of these structural elements.
Helix D of antithrombin is involved in binding to the cofactor
heparin (Jin et al., 1997), but binding of SPI-3 to HA clearly
requires different regions of the serpin.
Discussion
The finding that SPI-3 is physically associated with the
membrane protein HA suggests that SPI-3 interacts directly
with HA both on the surface of infected cells and on the outer
envelope of EEV. Binding of SPI-3 to HA embedded in
membranes allows SPI-3 to localize to the surface of virions
and cells without possessing a transmembrane domain. All
available data from mutants suggest that colocalization of
SPI-3 and HA at the cell surface is necessary for fusion
inhibition. As would be expected, removal of the SPI-3 signalsequence (Brum et al., 2003) or of the HATM domain (Fig. 4)
causes fusion, as does inactivation of HA, which also results in
failure of SPI-3 to localize to the plasma membrane (Brum et
al., 2003).
By testing N- and C-terminal deletion mutants of SPI-3, we
found that the shortest deletion of each series at either end
resulted in loss of fusion inhibition (Fig. 3), and we were
therefore not able to define a precise region of SPI-3 required
for fusion inhibition. However, deletions at opposite ends of
the mature SPI-3 protein had different effects on interaction
with HA. Deletion C2 at the C-terminus blocked the
association with HA (Fig. 10), which is required for correct
SPI-3 localization. In contrast, deletion SS-7N at the N-
terminus did not prevent binding of SPI-3 to HA (Fig. 10).
Despite the presence of SPI-3 SS-7N at the cell surface, fusion
was not inhibited (Fig. 3), suggesting that residues 23–70 of
SPI-3 are required for activity as a fusion inhibitor even when
the protein is correctly localized. SPI-3 mutants that fail to
inhibit fusion fall into two classes: those that are unable to bind
to HA and do not localize to the cell surface, and those that
bind HA and localize normally.
We attempted to identify other proteins associated with HA
and SPI-3 by attaching affinity tags that allowed tandem
affinity purification (TAP). The original TAP system (Puig et
al., 2001) was devised for use in yeast, and employs two
affinity tags, protein A (binds to IgG) and the calmodulin
binding peptide (CBP). The addition of these bulky tags at the
C-terminus of SPI-3 resulted in loss of fusion control, and this
construct was not pursued further. However, fusion of the
protein A and CBP tags to the C-terminus of HA did not
destroy activity in fusion inhibition, and a recombinant CPV
expressing HAwith protein A and CBP appended C-terminally
was constructed (HA-TAP). When HA-TAP protein was
purified by sequential IgG-Sepharose and calmodulin columns,
we isolated very pure HA-TAP protein together with small
amounts of SPI-3 protein that were identified by immunoblot-
ting, but no other associated protein that could be detected by
silver staining (data not shown). Although the system did
provide confirmation of the HA–SPI-3 interaction, it did not
allow us to detect any other proteins which might also be part
of the fusion inhibitory complex.
Evidence that SPI-3 and HA interact in uninfected BSR-T7
cells (Fig. 8) indicates that other viral proteins are not required
for association of these two proteins. We were unable to
recapitulate the HA/SPI-3 interaction by coexpression in vitro
using coupled transcription/translation, even in the presence of
microsomal membranes (data not shown). However, purified
SPI-3 protein added exogenously to cells expressing HA on the
surface was able to bind (Fig. 9), and the association could
therefore take place post-translationally. Our data do not
address the question of when during infection HA and SPI-3
first associate, and where this occurs. HA is expressed at both
early and late times (Brown et al., 1991) and SPI-3 (ORF K2L)
is expressed early based on expression of the protein in the
presence of cytosine arabinoside, an inhibitor which blocks
viral DNA synthesis and late gene expression (Turner and
Moyer, 1995). Transcriptional data indicate that SPI-3 is
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1998). Presumably both SPI-3 and HA transit through the ER
and Golgi, and could interact during this process.
The binding site in SPI-3 for HA is within a 229 amino acid
region toward the C-terminus (residues 145–373) based on
results with SPI-3 SS-8N (Fig. 10). The fact that SPI-3 RCL
substitutions do not affect binding to HA (Fig. 6) makes it
likely that the SPI-3/HA interaction differs from the interaction
of the serpin with susceptible proteases, which involves the
RCL region. Binding of SPI-3 to HA is also different than the
serpin antithrombin/heparin complex, which involves binding
of the heparin to the serpin helix D (Jin et al., 1997). The mAb
epitope for SPI-3 within residues 289–340 (Fig. 2) is still
accessible in the HA/SPI-3 complex both in solution (Fig. 5)
and when HA is embedded in the membrane (Figs. 1, 8, 9, and
10; Brum et al., 2003). The fact that binding of mAb and HA to
SPI-3 is not mutually exclusive strongly suggests that the
epitope does not overlap with the binding site in SPI-3 for HA.
Based on the model in Fig. 2C, the SPI-3 mAb may be
interacting with the front or base of SPI-3, and HA could be
binding to the back of the molecule, on the opposite side from
h-sheet A.
Binding of SPI-3 mAb to SPI-3 on the surface of
wtCPV-infected cells prevents control of cell–cell fusion
(Fig. 1), presumably by steric hindrance. However, the
mechanism by which the HA/SPI-3 complex regulates fusion
has yet to be determined. A28L is needed both for fusion
from without and fusion from within (Senkevich et al.,
2004b), processes which both apparently depend on virions
outside cells. We have been unable to detect any association
between SPI-3 and A28 following overexpression in the
VV-T7 system. This result is perhaps not surprising given
that SPI-3 is present in the outer envelope of EEV (Brum et
al., 2003) and A28 is found in the IMV envelope
(Senkevich et al., 2004a). How does the presence of
associated HA and SPI-3 proteins in the EEV envelope
and on the surface of infected cells regulate cell–cell fusion
mediated by the IMV A28 and H2 proteins? One explana-
tion is that the presence of the HA/SPI-3 protein complex
makes the EEV envelope less likely to rupture to release the
fusogenic IMV. Another possibility is that cells expressing
HA and SPI-3 may have a reduced ability to fuse with
virions. Either of these scenarios could minimize superin-
fection of virus-producing cells by released virions, which is
an attractive potential reason for the conservation of HA and
SPI-3 in orthopoxviruses. We are designing experiments to
address the mechanisms by which HA and SPI-3 regulate
cell–cell fusion.
Materials and methods
Cells and viruses
CV-1 cells (ATCC CCL-70) were maintained in GIBCO
Minimum Essential Medium with 5% fetal bovine serum (FBS)
and BSR-T7 cells (Buchholz et al., 1999) in Dulbecco’s
Modified Eagle Medium with 8% FBS, with 0.6 mg/ml activeG418 added at alternate passages to maintain expression of T7
RNA Polymerase. The Brighton Red strain of CPV was the
parent of CPVDSPI-3 and CPV HA (CPV HA::gpt) (Turner
and Moyer, 1992). vTF7-3DSPI-3 (Turner and Moyer, 1995)
was derived from vTF7-3 (Fuerst et al., 1986).
Antibodies
SPI-3 mAb 4A11-4A3 (Brum et al., 2003) was used as a
hybridoma supernatant for immunofluorescence, and as puri-
fied mAb to assess the effect on infected cells and for
immunoprecipitation. Polyclonal rabbit anti-HA antibody (Dr.
Samuel Dales) and mouse mAb 1H831 (Drs. H. Shida and Y.
Ichihashi) were used to immunoprecipitate HA. mAbC3
against A27L (Rodriguez et al., 1985) was from Dr. M.
Esteban. Anti-FLAG mAb M2 was from Sigma.
Plasmid constructs
SPI-3 was inserted into pTM1 (Moss et al., 1990)
downstream from the T7 promoter and EMCV IRES for
expression of wt SPI-3 (373 aa) (Turner and Moyer, 1995).
SPI-3 C-terminal deletions C2 (44 aa removed), C3 (87 aa
removed), C4 (150 aa removed), C5 (214 aa removed), and C6
(286 aa removed) were constructed by PCR, cloned into pTM1,
and sequenced to confirm the absence of PCR errors. pTM1-
SPI-3-FLAG, pTM1-SPI-3-C2-FLAG, and pTM1-SPI-3-C4-
FLAG were generated by subcloning into pTM1-FLAG, a
vector designed to add the FLAG tag at the end of the inserted
gene. The N-terminal SPI-3 deletions 7N (70 aa removed), 9N
(222 aa removed), and 10N (288 aa removed) were created
similarly, together with derivatives containing the 22 aa N-
terminal region of SPI-3 encompassing the signal peptide
(predicted to be residues 1–15). pTM1-SPI-3 SS-8N was
deleted for residues 23–144 of wt SPI-3.
The wt HA gene and HA()TM lacking residues 262–297
at the C-terminus including the transmembrane domain were
PCR amplified and inserted into pSC65 (Chakrabarti et al.,
1997) downstream from PE/L, a synthetic early/late promoter.
Isolation of virus recombinants
A cassette containing gfp linked to PE/L was inserted into
SPI-3 to create pBS-SPI-3::gfp, with residues 182–266 of SPI-
3 deleted. Cells infected with CPV HA were transfected with
pBS-SPI-3::gfp DNA, and green plaques of recombinant CPV
HA SPI-3::gfp isolated and purified.
Transcription/translation in vitro
Radiolabeled SPI-3 protein derivatives were made using
the Promega TNT T7 Quick Coupled Transcription/Transla-
tion System, with expression driven by the T7 promoter of
pTM1. For each 50 Al reaction, 30 ACi Tran35Slabel (MP
Biomedicals) containing 70% 35S-Met and 15% 35S-Cys was
used. The reaction was supplemented with 0.5 mM magne-
sium acetate.
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Infected cells were starved for 20 min in Met- and Cys-free
Eagle MEM (Sigma), then labeled with 50 ACi Tran35Slabel
per 35 mm well. Cells were harvested in PBS, and lysed in 100
mM NaCl, Tris–HCl, pH 8.0, 0.5% v/v NP-40 (IP buffer)
supplemented with 0.2 mM PMSF.
Immunoprecipitation
Radiolabeled protein made in vitro or from metabolic
labeling was incubated overnight at 4 -C with mAb in a total
volume of 200 Al IP buffer. Protein A-Sepharose (Amersham
Biosciences) was added for 1 h at 4 -C with continuous rotation
of the tubes. The protein A-Sepharose pellet with bound
antibody/antigen complex was washed three times in 1 ml IP
buffer, and labeled proteins released by heating at 95 -C for 5
min in SDS-PAGE sample buffer containing DTT. Proteins
were visualized by PAGE on 10% acrylamide gels, using
fluorography with Amplify (Amersham Biosciences) to reduce
exposure time to film.
Fusion assay
The transient assay for fusion inhibition was as described
(Turner and Moyer, 1995) except that Lipofectin (Invitrogen)
was the transfection reagent. CV-1 cells in 6-well plates were
infected with vTF7-3DSPI-3 (moi = 0.2) and transfected with 4
Ag plasmid DNA plus 12 Al Lipofectin, in a total volume of 1
ml medium without FBS. Medium with 5% FBS (2 ml per
well) was added at 5 h p.i., and fusion scored at 22 h p.i.
Immunofluorescence
Cells in 8-well slides (Lab-Tek) were transfected with
plasmid DNA (0.5 Ag per well for one DNA, or 0.3 Ag + 0.3 Ag
for two DNAs) using 2 Al LipofectAMINE 2000 (Invitrogen)
per well. The next day, cells were permeabilized with methanol
for 2 min, or left unpermeabilized. The cells were blocked with
PBS/3% BSA for 10 min, then reacted with the primary
antibody in PBS/3% BSA for 1 h at RT. SPI-3 mAb was used at
10 Ag/ml, and FLAG mAb at 7 Ag/ml.
After 3 PBS washes, cells were fixed with fresh PBS/4%
paraformaldehyde for 10 min, washed with PBS, reacted with
goat anti-mouse FITC secondary antibody (Jackson Immunor-
esearch Laboratories) at 1:100 for 30 min, then washed with
PBS three times before examination with a Zeiss Axiovert
200M inverted microscope.
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